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Abstract 
Background  
Achilles tendon injuries give rise to substantial long-lasting morbidity and pose considerable 
challenges for clinicians and patients, especially during the lengthy healing and recovery period. 
Current treatment strategies struggle to curb the burden of this injury on health systems and 
societal cost due to lengthy rehabilitation, absence from work and the risk of re-injury. Platelet Rich 
Plasma (PRP) is an autologous preparation that has been shown to improve the mechanobiological 
properties of tendons in laboratory and animal studies.  The use of PRP in musculoskeletal injuries is 
on the increase despite the lack of adequately powered clinical studies.  
Methods and Design 
We aim to undertake a multi-centre randomised controlled trial to evaluate the efficacy and 
mechanism of PRP in patients with acute Achilles tendon rupture. All adult patients with acute 
Achilles tendon rupture presenting within 12 days of the injury that are to be treated non-
operatively are potentially eligible to take part. A total of 214 consenting patients will be randomly 
allocated (1:1) via a remote web-based randomisation service to receive either PRP injection or 
placebo (imitation) injection to the site of the injury. All participants will be blinded to the 
intervention and will receive standardised rehabilitation to reduce the risk of efficacy interference 
from substantial variation in rehabilitation.  
Participants will be followed up with blinded assessments of muscle-tendon function, quality of life, 
pain and overall patient’s functional goals at 4, 7, 13, 24 weeks and 24 months post treatment.   The 
primary outcome is the heel rise endurance test (HRET), which will be supervised by a blinded 
assessor at 24 weeks. A subgroup of 16 participants in one centre will have needle biopsy under 
ultrasound guidance at 6 weeks. Blood and PRP will be analysed for cell count, platelet activation 
and growth factors concentration.  
Discussion  
This article presents the protocol for a multi-centre randomised controlled trial that is currently 
recruiting. It gives details of methods and describes the key procedures taken to avoid bias and to 
ensure validity.   
Trial registration 
ISRCTN: 54992179 Assigned: 12 January 2015, Clinicaltrials.gov: NCT02302664 Received: 18 
November 2014, UK Clinical Research Network Study Portfolio Database: ID 17850  
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Introduction 
Achilles tendon rupture (ATR) incidence is 21/100,000/year (1).  ATR accounts for 20% of all tendon 
ruptures, and leads to major healthcare and societal costs. The current treatment strategies are 
either augmentation with surgical suture, or immobilisation in a cast or boot. The mechanical and 
biological properties of healed tendons appear never to match those of the original intact tendons, 
leading to high risk of further injury (5-15%) or reduced function (2-4). Moreover, a Cochrane review 
reported mean ATR rehabilitation and work absence of 63-108 days (5).  
Platelet Rich Plasma (PRP) is a derivative of the patient’s own blood (autologous blood) that contains 
a supraphysiological concentration of platelets. Platelets contribute to injury healing by releasing an 
ordered sequence of growth factors, cytokines and an array of bioactive proteins in soluble and 
membrane-bound forms over the lifespan of the platelets (6, 7). These include transforming growth 
factor (TGF-ß1 and -ß2), platelet-derived growth factor (PDGF-AA, -AB and -BB), vascular endothelial 
growth factor (VEGF A and C), insulin like growth factor 1 (IGF-1) and epidermal growth factor (EGF) 
(7, 8). These factors recruit a range of cell types, including the injured tendon’s tenocytes, leucocytes 
and local stem cells, and promote the healing pathway. PRP enhances angiogenesis, stem cell 
homing,  local cell migration, proliferation and differentiation coupled with the deposition of 
proteins such as collagen which play a key role in enabling the restoration of normal tissue structure 
and function proliferation of human tenocytes (8, 9).  
PRP is prepared from autologous blood using Gravitational Platelet Sequestration (GPS) 
centrifugation, cell separators or selective filtration technology (plateletpheresis). Each preparation 
technique has been evidenced to result in significant differences in yields, concentration, purity, 
viability and activation status of the platelets (10).  Each of these variables will not only influence the 
eventual concentrations of the bioactive proteins but may also affect the clinical efficacy of each PRP 
preparation (11). We selected a centrifugation technique with highly standardised preparation 
protocol that offers consistently viable and active PRP with a high concentration of platelets and 
leukocytes (leukocyte rich PRP or L-PRP) (12).  
To date, there is only one randomised controlled trial (RCT) that has assessed PRP in Achilles tendon 
rupture, and in this study of 30 participants treated surgically, no effect of platelets on 
radioisometrical tendon contraction was seen (13); the use of PRP as an adjunct to open surgical 
repair may have obscured any effect of PRP on healing. In a case-control study of 12 athletes treated 
with PRP, positive effects at 32 months after treatment were demonstrated (14). Less tendon 
thickening and higher concentrations of TGF-β and other growth factors were seen in the 
intervention patients, who also regained range of motion faster and returned to gentle running 
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earlier (14). Systematic reviews (15, 16) concluded that there are encouraging signs that PRP could 
be developed as an effective tendon therapy, with potentially faster recovery and, possibly, a 
reduction in injury, with no adverse reactions described (16). Both reviews emphasised the need for 
an adequately powered RCT to establish PRP efficacy with disease-specific outcome measures.  
We describe the first multi-centre RCT to evaluate the efficacy and mechanism of PRP in patients 
with acute Achilles tendon rupture, where adequate power and robust, validated, objective and 
participant-reported outcome measures will ensure successful efficacy evaluation. Our aim is to 
investigate if the efficacy signal for PRP identified in basic science translates to improved mechanical 
muscle-tendon unit recovery in patients with acute Achilles tendon rupture. The primary objective is 
to evaluate the clinical efficacy of PRP in acute Achilles tendon rupture in terms of mechanical 
muscle-tendon function. The secondary objectives are to evaluate the clinical efficacy in terms of 
participant reported functional recovery, pain and quality of life; determine the key components of 
PRP that contribute to its mechanism of action; further understand in an immunohistochemical sub-
study the mechanisms of PRP which may account for its clinical efficacy; and identify the histological 
pathways that PRP may alter to exert its effects.  
Methods  
Study Design 
A prospective multi-centre, participant and outcome assessor blinded randomised placebo-
controlled superiority trial, which aims to evaluate the clinical efficacy of PRP in acute ATR in terms 
of recovery of the tendon function. 214 participants will be randomised to receive a PRP or placebo 
injection after attending the orthopaedic or trauma outpatient clinics within 12 days of the injury in 
at least 18 NHS hospitals. Two sub-studies are embedded in the main study to evaluate the 
mechanism of action and PRP components. The sub-studies are: (1) Immunohistochemistry analysis 
of ultrasound-guided needle biopsies from 16 participants at one centre (Oxford), and (2) Whole 
blood and PRP component analysis in all participants. A whole blood sample will be obtained from 
each participant prior to intervention. In the PRP group, a small volume of PRP will be used to 
analyse the biological components. Blood and PRP analysis will be carried out at a central specialised 
laboratory (Institute of Inflammation and Ageing Laboratory at the University of Birmingham).  
Through immunohistochemical, PRP and blood analysis, the potential mechanism of action will be 
studied to determine the key components of PRP that contribute to its effect. Linking the outcomes 
and the embedded laboratory analysis will allow us to evaluate the effect of variability of this 
biological product on the clinical outcome. 
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Study Participants 
All patients with acute Achilles tendon rupture attending outpatient trauma or orthopaedic clinic 
within 12 days of sustaining the injury are eligible for the trial if they meet all of the inclusion criteria 
and none of the exclusion criteria (Table 1). At least 18 UK National Health Service (NHS) hospitals 
will participate to recruit the required 230 patients. A list of participating sites to date can be found 
on the PATH-2 website (17) and in an online supplementary table. 
Table 1: Participants inclusion and exclusion criteria 
Inclusion criteria                              Exclusion criteria 
 Willing and able to give informed 
consent for participation  
 Age ≥ 18 years 
 Diagnosed with an acute complete 
Achilles tendon rupture 
 Presenting within and receiving 
study treatment within 12 days 
post injury 
 Patients in whom the decision has 
been made for non-operative 
treatment  
 Ambulatory prior to injury without 
the use of walking aids or 
assistance of another person 
 Able and willing to comply with all 
study requirements 
 Able to attend the 24-week follow-
up at a PATH-2 study hospital site 
 Achilles tendon injuries at the insertion to the 
calcaneum or at the musculotendinous junction  
 Previous major tendon or ankle injury or deformity 
to either lower leg 
 History of diabetes mellitus 
 Known platelet abnormality or haematological 
disorder 
 Current use of systemic cortisone or a treatment 
dose of an anticoagulant 
 Evidence of lower limb gangrene/ulcers or 
peripheral vascular disease 
 History of hepatic or renal impairment or dialysis 
 Pregnant or breast feeding 
 Currently receiving or has received radiation or 
chemotherapy within the last 3 months  
 Has inadequate venous access for drawing blood 
 Has any other significant disease or disorder which, 
in the opinion of the recruiting clinician, may either 
put the participant at risk because of participation in 
the study, or influence the result of the study, or 
influence the patient’s ability to participate in the 
study 
 
Centre Recruitment  
A minimum of 18 NHS hospital orthopaedic trauma/outpatient clinics will recruit 214 participants for 
the trial. Each site will identify a surgeon to act as PATH-2 Principal Investigator (PI).   The PI oversees 
the study protocol implementation at each site, utilises links with local physiotherapy departments 
to facilitate the standardised rehabilitation and arranges for a blinded physiotherapist who will be 
the assessor for the HRET primary outcome measurement. The trial team will assess each centre to 
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ensure the site is equipped with appropriate resources to deliver the project and meet recruitment 
targets. 
Participant Recruitment 
Participants will be identified in the outpatient trauma or orthopaedic clinic. The treating surgeon or 
extended scope physiotherapist will confirm the diagnosis, appropriateness for conservative 
treatment and study eligibility. A member of the research team at the site will carry out the 
informed consent process, baseline data collection and randomisation.  
Informed consent 
The timeframe between attending clinic and receiving the intervention is relatively short. To help 
raise awareness of the study during the clinic wait, sites will be provided with written study 
participant information (including posters) to display in clinic where potential participants are 
waiting to be seen by the surgeon or extended scope physiotherapist. 
The attending surgeon or extended scope physiotherapist will meet with the participant for the 
clinical examination and decide if the management will be operative or non-operative. If non-
operative, participants will be informed of the study and given a Patient Information Sheet (PIS). The 
participant will be allowed as much time as practically possible in this type of acute injury to 
consider the information, and will have the opportunity to ask questions of the attending clinician 
and a member of the research team.  
The person who obtains the consent must be a registered health or medical practitioner who is GCP 
trained and has been authorised to do so by the PI. In most sites this is a research nurse or 
physiotherapist or surgeon who will be a part of the local NHS Trust or the local National Institute of 
Health Research (NIHR) clinical research network. The participant must sign and date the informed 
consent form before any study specific procedures are performed. Participants will also be asked to 
consent to use of their data, biological specimens and videos of their HRET test (view is of leg only). 
A copy of the signed Informed Consent Form will be given to the participants, and one copy will be 
sent to the study coordinating team. The original signed Consent Form will be retained in the 
medical notes, and a copy held in the Investigator Site File (ISF).  
Baseline Assessment 
Baseline data are collected immediately following confirmation of eligibility and consent. 
Background and demographic information are collected including: general health, current 
medication, allergies, smoking, alcohol use, age, sex, employment status, type of employment, 
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activities of daily living, sport and recreational activities prior to injury, the activity that led to the 
injury, previous history, height and weight. The Achilles Tendon Rupture Score (ATRS), a validated 
and responsive participant reported outcome measure (PROM) is collected (18, 19). In addition, 
participant reported outcome measures: Patient-specific functional scale (PSFS) (20, 21), Visual 
Analogue Score (VAS) pain indicator (22), and the acute version SF-12 assessment (23). The latter is 
collected as recalled before injury and also on the day of treatment (Table 2). The recall of SF-12 
health status and physical ability in the 4 weeks prior to the injury is a valid method considering the 
acute occurrence of the injury and the short period to recruitment (up to 12 days).  
Randomisation 
Participants will be randomly allocated (1:1) to the two groups (treatment and placebo groups) via a 
central computer-based allocation randomisation system provided by the Oxford Clinical Trials 
Research Unit (OCTRU). The randomisation will use minimisation, stratified by study site and age 
group (<55 and ≥55), and with a probabilistic element of 0.8 to reduce predictability for this multi-
centre trial whilst retaining balance within centre and ensure overall balance at the end of the study 
(24). Participants will remain blind to their allocated treatment throughout the study. 
Interventions 
The two trial groups are: 
 PRP injection (treatment group): After local anaesthetic injection, PRP is injected into the 
tendon rupture gap. 
 Imitation injection (placebo group): After local anaesthetic injection, a needle is introduced 
into the tendon rupture gap, held briefly and withdrawn without injecting and without 
disturbing the biological haematoma.  
Immediately after randomisation, up to 55 ml of venous blood is withdrawn from the participant 
regardless of the random allocation. The exact amount of blood and the volume of PRP injected are 
not stated in the participant information sheet (PIS) as this information has the potential to unblind 
participants.  
PRP will be prepared from the venous blood by a study-specific centrifuge (MAG 200 MAGELLAN® 
Autologous Platelet Separator, Arteriocyte Medical Systems) in or near the clinic (Figure 1). This 
device has been found to produce around a 5-fold concentration of platelets with 76% platelet 
recovery (12). This is a fully automated system, requiring a sterile PRP disposable kit (MDK 300 / 
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MDK 300-1, Arteriocyte Medical Systems) and a single preparation step, reducing the risk of protocol 
deviation while in use.  
Both interventions will be delivered by a clinician or extended scope physiotherapist while 
maintaining the participant’s blinding to the allocation. Both interventions are delivered by the same 
technique. The patient is positioned lying face down on a treatment bed with the tendon exposed. 
The tendon gap is palpated clinically to identify the injection site. The area is cleaned and 1-2 ml 
local anaesthetic is used to anaesthetise the skin only. In PRP injection group, half of the PRP is 
injected in the tendon gap (figure 1:D) and the remaining PRP is kept for analysis. In the imitation 
group, the same size needle is inserted into the tendon gap, held briefly and withdrawn without 
injecting anything. 
As this study requires a single treatment, adherence to the protocol consists of the participant 
receiving the allocated treatment. This will be monitored, and every instance of the participant not 
receiving the allocated treatment will be investigated. Unless they request to withdraw, these 
participants will be retained in the trial, to avoid missing data and for follow-up. However, if a 
participant is unable to receive a PRP injection for any technical reasons they will receive an 
imitation injection and this will be recorded. 
Training in delivery of the PRP injection and the imitation injection will be provided by the trial team 
and a step-by-step manual is provided to each site. Video training materials are available to site staff 
via an access-controlled website (25) but not supplied here because of the potential for unblinding.  
Blinding Procedure  
It will not be possible to blind the research nurse, surgeon or extended scope physiotherapist 
involved in treatment preparation or delivery due to the nature of the intervention. However, the 
participant and the assessor for the primary outcome are blinded. The participant will be shielded 
from the injection preparation as this is done in another room or while the participant is waiting 
outside the clinic. To reduce the risk of unblinding, participants in both intervention groups will wait 
for approximately 17 minutes, the duration of a cycle for the PRP preparation, and not be in direct 
sight of the machine. If the machine is not out of earshot, a dummy cycle will be run on the machine. 
The participant will receive the injection whilst lying face down and visually obscured from the 
procedure. The primary outcome assessor will not be aware of allocation when they perform the 
HRET at 24 weeks after treatment. 
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Figure 1: Making autologous platelet-rich plasma (PRP) in the PATH-2 Study. A: a whole blood 
sample is taken; B: the Magellan Autologous Platelet Separator System is used to produce PRP; C: the 
resulting PRP is collected in a syringe for injection into the Achilles tendon rupture gap; D: the 
injection is delivered in the tendon rupture gap.  
Standardisation of other treatments 
All participants receive standard care at the participating site. Standard treatment for the non-
surgical population is usually immobilisation of the ankle in a cast, splint or  boot during the initial 
clinic visit. Immediately after the intervention (PRP or imitation) the ankle will be immobilised in a 
cast, splint or boot. Standardisation of key elements of rehabilitation is required for this trial to 
reduce the risk of efficacy interference from substantial variation in rehabilitation. The following 
milestones are standardised: 
 Duration of initial ankle immobilisation post intervention is at least 3 weeks   
 Position of the foot and ankle in equinus during the initial immobilisation  
 Referral to physiotherapy for rehabilitation  
 Avoidance of rigid full-time immobilisation or non-weight bearing for more than 6 weeks  
Standardisation will not be required for the ankle splinting method or device, when weight bearing is 
commenced or the specific exercise prescription. We will standardise rehabilitation by providing 
D 
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guidance to surgeons and physiotherapists in written form. Monitoring adherence with these 
guidelines will be assessed by asking participants questions relating to progress with rehabilitation 
during follow-up. 
Objectives and Outcome Measures 
The primary objective is to evaluate the clinical efficacy of PRP in acute ATR in terms of muscle-
tendon function. The primary outcome measure is work in joules derived from the HRET, which is a 
validated objective measure of Achilles tendon muscle unit function at 24 weeks to evaluate efficacy 
(26). Preceded with a warm up activity of walking for 5 minutes, the test is first performed on the 
uninjured limb and then on the injured side. The HRET involves the participant standing on one leg 
on a 10° incline box, raising and lowering the heel repeatedly at a rate of 30 raises per minute guided 
by a digital metronome until task failure. Vertical displacement data from the movements are 
obtained using a computer-controlled linear encoder (Encoder, MUSCLELAB™, Ergotest Innovation 
A.S., Porsgrunn, Norway) that measures the height of each heel-rise repetition and integrates the 
data into custom-made software (PATH-2, MUSCLELAB™, Ergotest Innovation A.S., Porsgrunn, 
Norway). Work (J) is calculated as the product of body mass (kg, measured on class III scales), total 
vertical displacement (m), and the constant 9.807 converting kilopond-metres to joules. We will also 
report the number of repetitions and maximum heel rise height (cm). The performance of the 
injured limb for each of the three variables will be expressed relative to the uninjured limb by 
computing a limb symmetry index (LSI): 𝐿𝑆𝐼= (𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑖𝑚𝑏 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 / 𝑢𝑛𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑖𝑚𝑏 
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡) × 100. Participants are asked to stop by the assessor if any of the following is 
observed: volitional stopping due to fatigue; inability to keep pace with the metronome or maintain 
full knee extension of the standing leg; or using more than fingertip support against the wall. The 
assessor uses verbal prompts if the above are observed, and stops the test if the participant does 
not respond to two consecutive prompts. The test will be standardised through providing study-
specific encoder and software, HRET training manual and one-to-one training to the blinded assessor 
in each centre. Since the encoder is a very sensitive device, it records even minimal movements that 
might not correspond to actual heel rises. To dismiss potential measurement errors, two researchers 
(at least one being a physiotherapist) blinded to treatment allocation will independently review the 
videos of all assessments and discount any invalid repetition included in the HRET data. The primary 
and secondary outcome measures are presented in Table 2. 
In the two sub-studies the outcome measures are defined according to the sub-study analysis.  The 
whole blood and PRP component sub-study includes analysing full blood cell count (red cells, 
platelets and white cells) in all participants in both groups and analysing PRP components in the PRP 
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group.  PRP analysis includes: cell count, platelet activation status (resting and fully activated) as a 
measure of quality and relevant growth factors concentrations (PDGF, IGF-1, VEGF, FGF and TGF-β). 
All blood and PRP samples will be anonymised, placed in secure biological sample transport 
packaging and sent via tracked courier to a central laboratory (Institute of Inflammation and Ageing 
Laboratory at the University of Birmingham) for analysis.  
In the Immunohistochemistry sub-study: 16 participants in one centre (Oxford) who have given 
informed consent to undergo the sample collection procedure will have tendon needle biopsy under 
ultrasound guidance at week 6 post intervention. The patients for this sub-study will be the first 8 
consented in each arm at the Oxford site only and the procedure is carried out by an experienced 
radiologist. Analysis includes tissue morphology, proliferation, apoptosis, vascularity, metabolic 
indicators, and stem cell marker. The tissues will be stored for future analysis of relevant markers.   
Data will be collected for all participants including those who do not receive the allocated 
intervention, unless they have withdrawn consent for follow-up. In order to obtain as complete a set 
of outcome data as possible, several attempts will be made to contact participants by phone for 
follow-up at each time point and if they are not available the questionnaire will be sent by post. 
Table 2: Primary and secondary outcome measures 
Primary outcome measure: Heel-raise endurance test (HRET) 
Measurement  Work (joules) of each limb in heel-rise test 
Analysis variable Limb symmetry index (LSI) 
Description 
𝐿𝑆𝐼 =
𝐼𝑛𝑗𝑢𝑟𝑒𝑑 𝐿𝑖𝑚𝑏 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡
𝑈𝑛𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝐿𝑖𝑚𝑏 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡
 𝑥 100 
Method of aggregation Mean ± SD 
Time point 24 weeks post intervention 
HRET other variables Number of heel raises performed by each limb 
Maximum displacement during the HRET for each limb (cm) 
Secondary outcome measures 
Time point Outcome measure  
Baseline ATRS, PSFS, SF-12 (pre and post injury), VAS (pre-treatment) 
Sub-study 1: Blood sample ( both groups), PRP analysis (PRP group) 
2-Weeks Daily record of post-treatment pain using Daily Pain Diary (VAS) 
6 Weeks  Sub-study 2: Tendon needle biopsy under ultrasound guidance analysis  
(16 participants, 8 in each arm, central site) 
Immunohistochemistry analysis  
Weeks 4, 7 and 13 ATRS, PSFS and SF-12  
recorded by telephone call or during outpatient visit 
Week 24 ATRS, PSFS, SF-12, HRET 
conducted via assessment at outpatient visit  
Month 24 ATRS, PSFS and SF-12  
12 
 
recorded by telephone call 
 
Study Flowchart 
The patient pathway and main study activities are shown in Figure 22. 
 
Figure 2: The patient pathway for the main study. The sub-studies are not shown in this diagram  
13 
 
Safety Reporting 
Because PRP is prepared from autologous blood, concerns of disease transmission and immunogenic 
reactions are eliminated. Although there have been no serious adverse events (SAEs) related to 
using PRP reported in the literature, we have systems in place to monitor all adverse and serious 
adverse events. Adverse events (AEs) will be collected during the study treatment episode and staff 
should report any events they become aware of up to and including the 24 months follow-up 
appointment. SAEs must be reported to the Chief Investigator within 24 hours of the local research 
team becoming aware of the event. Participants will be asked if they have experienced any 
complications during follow-up data collection (Table 3, Table 4). Unblinding of participants is not 
anticipated unless there are compelling medical or safety reasons. If unblinding is requested by a site 
PI; the CI and OCTRU will make a decision based on the reasons for the request. Deviations from 
protocol and other unexpected events will be recorded on an incident form and assessed by the 
study team for implications for the study. 
Table 3: Serious adverse events 
An adverse event is considered a serious adverse event if it satisfies at least one of the 
following criteria 
 results in death 
 is life-threatening 
 requires in-patient hospitalisation or prolongation of existing hospitalisation  
 results in persistent or significant disability/incapacity  
 results in  congenital anomaly or birth defect  
 Another medical event judged important in the opinion of the Investigator 
 
Table 4: Adverse events not qualifying as SAEs 
Foreseeable AEs                                                                         Unforeseeable AEs 
May be reported if related to study treatment 
 Bruising and discomfort at the venesection site 
 Mild discomfort or minor bleeding from ATR site 
following injection 
 Syncopal (fainting) episode associated with venesection 
or tendon injection  
 Discomfort at ATR site during rehabilitation 
 Technical complications of the lower leg casting and 
splinting 
 Consequences of depending on walking aids 
 Swelling or bruising of the lower leg and foot  
 Deep vein thrombosis in a lower limb  
 Re-rupture of the treated Achilles tendon  
Will be reported if related to treatment. 
Examples: 
 Serious infection of ATR injection site 
 Skin breakdown or ulceration of treated 
lower leg other than “plaster sores” 
 Severe pain requiring more than simple 
analgesia beyond 10 days after injection 
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Data Management 
All data will be processed according to the Data Protection Act 1998, and all documents will be 
stored safely in confidential conditions. Data will be collected from participants and site personnel 
via paper case report forms (CRFs) which will be returned to the central trial office by post using a 
Freepost address (pre-paid). Blood samples and needle biopsy samples sent for analysis will be 
anonymised at source and only identified using the unique study number and participant initials. The 
HRET test data are transferred via the linear encoder linked to a study-dedicated laptop then 
transferred from each site to Oxford by an encrypted USB following each participant HRET and the 
original data remains on the site laptop. Blood and PRP samples will be stored at the Centre for 
Translational Inflammation Research at the Birmingham University Research Laboratory and 
disposed of at the end of the study. Needle biopsy samples for those participants taking part in the 
sub-study (n=16), will be stored in the Oxford Musculoskeletal Biobank. Data provided from the 
blood sample analysis or biopsy samples analysis will be entered into the study database in Oxford. 
All data transfers will use appropriate password protected and/or encrypted files. The study 
management team will conduct data entry into a study-dedicated database which is developed and 
maintained by the Oxford Clinical Trials Research Unit.  
Sample Size and Statistical Analysis 
230 patients (115 in each arm) will provide 80% power to detect a standardised difference of 0.5 in 
the LSI from the HRET measure of work at 24 weeks post randomisation and with 5% (2-sided) 
significance allowing for 20% loss to follow-up. This is based on previous data (18) where a clinically 
important difference of 10% with SD of 20 was observed and blinded interim data analysis that 
showed SD of 24. This sample size will also provide 90% power and 5% (2-sided) significance to 
detect an effect size of 0.5 in the ATRS, based on a difference of 11 and SD of 21.4 (18). All 
comparative results will be presented as summary statistics with 95% confidence intervals and 
reported in accordance with the non-pharmacological extension to the CONSORT statement (27, 28). 
The primary statistical analysis will be carried out on the basis of intention-to-treat (ITT). The time 
window for collecting the HRET will be 2 weeks before the 24 weeks time point and up to 8 weeks 
after. The primary analysis to investigate the adjusted effect of PRP on ATR recovery will be 
multivariate linear regression, using the LSI as dependent variable, treatment as the main 
independent variable and the stratification factors plus other prognostic factors as additional 
independent variables. If the primary outcome data are normally distributed, the two groups (PRP x 
imitation injection) will also be compared using an unpaired Student’s t-test to explore the 
unadjusted effect of the intervention. If data on the primary outcome are not normally distributed, 
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the first approaches will be data transformation, but if normality cannot be achieved a non-
parametric statistical test without adjustment will be used.  
The PROMs (secondary outcomes) will be analysed in a linear mixed model longitudinal framework 
to allow all data collected at all time-points to be taken into account. This is a robust procedure that 
deals with some missing values; however, missing data imputation will be carried out if necessary. 
Similarly to the primary outcome, unadjusted analysis and data transformation (if necessary) will 
also be performed for all continuous secondary outcomes. Descriptive statistics (such as means and 
standard deviations for continuous variables and frequencies and proportions for categorical or 
binary variables) will be used to describe the baseline characteristics of the participants in the two 
study groups; however no formal statistical tests will be used to compare the groups. 
For the two sub-studies, primary analyses will primarily be descriptive and the relationship between 
various biomarkers and clinical outcomes will be explored. 
A separate Statistical Analysis Plan (SAP) will contain full details of all statistical analyses and will be 
prepared early in the trial, agreed with the Data and Safety Monitoring Committee (DSMC), and 
finalised prior to the primary analysis database lock and before unblinding of the data. Any changes 
at this time will be incorporated into the final SAP and signed off as per current OCTRU SOPs. Any 
changes/deviations from the original SAP will be described and justified in the protocol and/or in the 
final report, as appropriate. Comparative outcome interim analyses are not planned unless 
requested by the DSMC. 
Ethics and Dissemination 
The Oxfordshire Research Ethics Committee has given approval for this study (Oxfordshire Ethics 
committee A, reference 14/SC/1333). This trial will be conducted in accordance with the ethical 
principles that have their origin in the Declaration of Helsinki, and that are consistent with Good 
Clinical Practice and the applicable requirements as stated in the Research Governance Framework 
for Health and Social Care (2nd edition 2005). The study may be monitored, or audited in accordance 
with the current approved protocol, GCP, relevant regulations and standard operating procedures 
(29). An independent DSMC is established to safeguard the interests of trial participants, potential 
participants and future patients, to assess the safety and efficacy of the interventions during the 
trial, and to monitor the overall conduct of the trial, protecting its validity and credibility. DSMC will 
adopt the DAMOCLES charter (30) and meet at least annually, with an option to increase if specific 
concerns arise. Local NHS trust approval and contract with the sponsor is required before 
recruitment initiation at each site.  The study may be audited by the sponsor or the clinical trials 
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unit. The study office team will conduct monitoring visits to sites as defined in the Risk Assessment 
and Monitoring Plan.  
The trial will be reported in accordance with the CONSORT statement (31) and its extensions relating 
to non-pharmacologic studies (27, 32) and TIDieR guidelines for intervention description and 
replication (33). A summary of the trial outcome will be disseminated to trial participants on relevant 
websites, and by email, where an email address is provided. In addition to the NIHR monograph 
report, the results will be published in peer-reviewed medical literature, and may be presented at 
relevant national and international conferences.  
Amendments to the protocol 
Amendments will be handled through HRA procedures. Two substantial amendments have been 
implemented since the study began (Error! Reference source not found.). The first amendment was 
submitted prior to commencement of the trial to add additional information, rehabilitation guidance 
and blinding assessment. The second amendment was performed after 40 patients were recruited to 
change recruitment criteria, clarify diagnosis, clarify anticoagulation, and update the randomisation 
mechanism and statistical plan.  The change to randomisation was required due to imbalance in 
participants’ age group stratum following a systems issue. The underlying systems issue was fixed 
and a change to the randomisation strategy was implemented to avoid this imbalance being 
preserved throughout the study. The randomisations allocated prior to the change were not altered. 
This approach was reviewed and approved by the Sponsor, DMSC, TSC and the Ethics Committee. 
Table 6: Protocol Substantial Amendments   
Amendment / date Nature of amendment  Rational  
 SA1  
 15 June 2015 
 Record maximum height and 
number of heel rises in HRET 
 Provide  additional validation of the 
outcome measure  
 Ask patient which intervention they 
think they received, in 24 week 
post-assessment questionnaire 
 Assessment of success of blinding 
strategy 
 Stipulate guidelines for 
rehabilitation 
  To accommodate local preferences while 
ensuring the integrity and success of the 
trial 
 Added guidance if allocated 
intervention cannot be given 
 Guidance was omitted in original 
protocol version 
 Clarifications on the nature of the 
injury  
 Clarify injury type 
SA2 
13 May 2016 
 Change inclusion criteria   Increase upper age limit with 
requirement of ambulatory status  
  Increase recruitment period  12 days post injury instead of 7 
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  Extended scope physiotherapists 
can administer the intervention 
 Pragmatic approach to accommodate for 
clinical practice  
  Clarification of the ATR diagnosis  Clarification of the rupture location 
  Clarification of anticoagulation  VTE prophylaxis requirement  
  randomisation and statistical 
alterations 
 Approval of randomisation and statistical 
plan 
SA03  Extended  24 Months follow up  To study PRP on effect on the quality of 
the repaired Achilles tendon at 2 years 
post injury. 
SA04  Extend recruitment by 2 month 
 Increase sample size to 230 
 DSMC clinded interim data analysis found 
HRET SD is 24 with larger variability in 
data. Sample size increased to guarantee 
80% POWER 
SA05    
 
Discussion 
This multi-centre trial opened to recruitment in July 2015 and will reach recruitment targets in 
September 2017. The trial is due to report results in February 2018.  
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